AB InBev Financial Results
The sensitivity of the defined benefit obligation to changes in the weighted principal assumptions is:
Million US dollar
Discount rate
Price inflation
Future salary increases
Medical cost trend rate
Mortality
Change in
assumption
2022
Increase in
assumption
Decrease in
assumption
117
0.5%
0.5%
0.5%
1%
One year
(271)
94
295
20
25
(101)
(19)
(22)
147
(149)
The above are purely hypothetical changes in individual assumptions holding all other assumptions constant: economic
conditions and changes therein will often affect multiple assumptions at the same time and the effects of changes in key
assumptions are not linear.
Sensitivities are reasonably possible changes in assumptions, and they are calculated using the same approach as was
used to determine the defined benefit obligation. Therefore, the above information is not necessarily a reasonable
representation of future results.
The fair value of plan assets at 31 December consists of the following:
Million US dollar
Government bonds
Corporate bonds
Equity instruments
Property
Insurance contracts and others
Quoted
2022
Unquoted
Total
Quoted
2021
Unquoted
Total
34%
34%
34%
34%
30%
30%
34%
34%
24%
24%
24%
24%
7%
7%
4%
4%
4%
1%
5%
2%
2%
4%
91%
8%
100%
94%
6%
100%
AB InBev expects to contribute approximately 182m US dollar for its funded defined benefit plans and 69m US dollar in
benefit payments to its unfunded defined benefit plans and post-retirement medical plans in 2023.
24. Share-based payments
Different share-based programs allow company senior management and members of the board of directors to receive or
acquire shares of AB InBev, Ambev or Budweiser APAC. AB InBev has three primary share-based compensation plans,
the share-based compensation plan ("Share-Based Compensation Plan"), the long-term restricted stock unit plan for
directors ("Restricted Stock Units Plan for Directors"), and the various long-term incentive plan for executives ("LTI Plan
Executives"). For all option plans, the fair value of share-based payment compensation is estimated at grant date, using a
binomial Hull model, modified to reflect the IFRS 2 Share-based Payment requirement that assumptions about forfeiture
before the end of the vesting period cannot impact the fair value of the option. These share-based payment programs
relate to either AB InBev shares or American Depository Shares (ADSS) as underlying equity instruments.
All the company share-based payment plans are equity-settled. Amounts have been converted to US dollar at the average
rate of the period, unless otherwise indicated.
Share-based payment transactions resulted in a total expense of 448m US dollar for 2022, as compared to 510m US dollar
for 2021, which included an amount of 72m US dollar that was reported in non-underlying items representing the IFRS 2
cost related to the Zenzele Kabili scheme. For more details, refer to Note 21 Changes in equity and earnings per share.
AB INBEV SHARE-BASED COMPENSATION PROGRAMS
Share-Based Compensation Plan for Executives
Under this plan, members of the Executive Committee and other senior employees receive their bonus in cash but have
the choice to invest some or all of the value of their bonus in AB InBev shares, referred to as voluntary shares. The voluntary
shares are entitled to dividends from the date of grant and are subject to a lock-up period of three years. They are granted
at market price, to which a discount of up to 20% is applied. The discount is delivered in the form of restricted Stock Units
("RSUS") (Discounted Shares). Executives who invest in Voluntary Shares also receive one and a half matching shares for
each voluntary share invested up to a limited total percentage of each executive's variable compensation. These matching
shares are also delivered in the form of RSUs (Matching Shares). The RSUs relating to the Matching Shares and the
Discounted Shares vest over a 3-year period and are subject to specific restrictions or forfeiture provisions in the event of
termination of service.
71View entire presentation